InvestmentPitch Media Video Discusses FSD Pharma's Unveiling of Video Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Mouse Models - Video Available on Investmentpitch.com

·2 min read

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is now sharing pre-clinical data demonstrating the potentially disease-modifying effects of Lucid-MS, the company's lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS.

InvestmentPitch.com has produced a "video" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "FSD Pharma" in the search box.



Cannot view this video? Visit:
http://www.investmentpitch.com/video/1_8dcawbgr/FSD-Pharma-unveils-videos-demonstrating-positive-effects-of-Lucid-MS-in-treating-multiple-sclerosis-in-pre-clinical-mouse-models

Based on more than a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. In order to demonstrate the unique potential therapeutic value of Lucid-MS, the company has released a video explaining its pre-clinical results.

As shown in the video, the subject mouse that received Lucid-MS demonstrated an improvement in clinical score when compared with the mouse that received the placebo, and by the end of the study, the subject showed clinical signs similar to those in a healthy mouse.

Dr. Lakshmi P. Kotra, Ph.D, Lucid Psycheceuticals CEO, stated: "Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models. This effect holds good promise for further development as a potential treatment for MS, and the biochemical mechanism of Lucid-MS represents a potential industry first in treating MS. We are eager to advance Lucid-MS to the clinic as quickly as we can."

FSD Pharma is also advancing the development of its other drug candidates, including Lucid-PSYCH, a psycho-active molecule targeted to treat Major Depressive Disorder, and FSD-PEA, an anti-inflammatory compound.

The shares are trading at $1.55 on the Canadian Securities Exchange. For more information, please visit the company's website, www.FSDpharma.com, or contact Zeeshan Saeed, President and Founder, at 416-854-8884 or by email at zsaeed@FSDpharma.com.

For investor relations in Canada email IR@FSDpharma.com. In the United States, investor relations is handled by KCSA Strategic Communications, at FSDpharma@kcsa.com.

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106425

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting